Difference between revisions of "Part:BBa K5330020"
 
(6 intermediate revisions by the same user not shown)
Line 2: Line 2:
 
<partinfo>BBa_K5330020 short</partinfo>
 
<partinfo>BBa_K5330020 short</partinfo>
  
−
This part along with BBa_K5330021 are the two components of a test for <I> Mycobacterium avium subspecies paratuberculosis </I> (MAP.) This part is composed of a type 2A encapsulin (from MAP) with a linker to a SmBiT. The SmBiT is half of a split luciferase. This acts as a reporter system for cage formation of Encapsulins linked to either LgBiT or SmBiT which when they come together in the presence of NanoGlo reagents, they produce light.  
+
This part along with BBa_K5330021 are the two components of a test for <I> Mycobacterium avium subspecies paratuberculosis </I> (MAP.) This part is composed of a type 2A encapsulin (from MAP) with a linker to a SmBiT with a total molecular weight of 37kDa. The SmBiT is half of a split luciferase. This acts as a reporter system for cage formation of Encapsulins linked to either LgBiT or SmBiT so when they come together in the presence of NanoGlo© reagents, they produce light. With both SmBiT-Encap2A and LgBiT-Encap2A present in the test, light output is detected (see Figure 1).
−
With both SmBiT-Encap2A and LgBiT-Encap2A present in the test, light output is detected. When a blood sample of a cow infected with Johnes diseases is introduced into this solution, there should be a detected loss of light. This is because Encapsulin monomers from MAP will rearrange to incorporate our engineered monomers (SmBiT-Encap2A and LgBiT-Encap2A) resulting in distance being introduced between halves of the split luciferase and either less or no light produced at all.
+
  
 
<html>
 
<html>
Line 9: Line 8:
 
</html>
 
</html>
 
''Figure 1: Negative Test Diagram (no presence of MAP Encapsulin monomers).''  
 
''Figure 1: Negative Test Diagram (no presence of MAP Encapsulin monomers).''  
 +
 +
When a blood sample of a cow infected with Johnes diseases is introduced into this solution, there should be a detected loss of light. This is because Encapsulin monomers from MAP will rearrange to incorporate our engineered monomers (SmBiT-Encap2A and LgBiT-Encap2A) resulting in distance being introduced between halves of the split luciferase and either less or no light produced at all (see Figure 2). This occurs due to the lability in exchange of monomers in encapsulin cages allowing interconversion of MAP encapsulin and our engineered ones.
  
 
<html>
 
<html>
Line 32: Line 33:
 
<center><img src = "https://static.igem.wiki/teams/5330/registry-parts/screenshot-2024-09-26-at-12-03-56-pm.png"></center>
 
<center><img src = "https://static.igem.wiki/teams/5330/registry-parts/screenshot-2024-09-26-at-12-03-56-pm.png"></center>
 
</html>
 
</html>
−
''Figure 3: Type 2 Encapsulins (right) and Type 1 Encapsulins in their cage formations(1).''  
+
''Figure 3: Type 2 Encapsulins (left) and Type 1 Encapsulins (right) in their cage formations(1).''  
  
 
Then we decided how long we wanted our linker; did we want more flexibility, or did we want a bit more control over how far we can reach with the two split luciferase parts. We found a paper(2) where they attached NanoLuc to type 1 encapsulins to detect cage formation. From there, we copied their linker design (for which they did not describe the rational for) to attach our split luciferase parts and our type 2A encapsulin monomers.
 
Then we decided how long we wanted our linker; did we want more flexibility, or did we want a bit more control over how far we can reach with the two split luciferase parts. We found a paper(2) where they attached NanoLuc to type 1 encapsulins to detect cage formation. From there, we copied their linker design (for which they did not describe the rational for) to attach our split luciferase parts and our type 2A encapsulin monomers.
Line 41: Line 42:
 
''Figure 4: Type 2 Encapsulins attached to SmBiT.''  
 
''Figure 4: Type 2 Encapsulins attached to SmBiT.''  
  
−
We have since encountered problems in our protein purification leading us to believe that our His tag should be on the C terminus (rather that the N terminus it currently is on.) This hinderance means that it is highly likely that the protein purification thus far will have produced monomers/cages that are not correctly formed and that could possibly be aggregates. This part is currently produced in a PC2 lab due to the production being from a GMO. This part was produced in SHuffle® T7 Competent E. coli due to their enhanced protein expression and folding ability. Due to the NEBuilder not up taking the gene insert into the plasmid, we were unable to purify the protein in time to perform the assay with SmBiTEncap to see if light would be produced.
+
We have since encountered problems in our protein purification using His tag purification on immobilised metal affinity chromatography. We think our His tag should have been on the C terminus (rather that the N terminus it currently is on.) This has lead to a less efficient purification with a lot of protein lost in the follow-through. For information of experimental data collected from this part, see the design page.  
 +
 
 +
This part is currently produced in a PC2 lab due to the production being from a GMO. This part was produced in SHuffle® T7 Competent E. coli due to their enhanced protein expression and folding ability. As of the registry freeze, we are yet to achieve proof of concept due to complications in LgBiT purification.
  
 
== Sources ==
 
== Sources ==
Line 53: Line 56:
 
(1) Nichols, R. J.; LaFrance, B.; Phillips, N. R.; Radford, D. R.; Oltrogge, L. M.; Valentin-Alvarado, L. E.; Bischoff, A. J.; Nogales, E.; Savage, D. F. Discovery and Characterization of a Novel Family of Prokaryotic Nanocompartments Involved in Sulfur Metabolism. eLife 2021, 10, e59288. https://doi.org/10.7554/eLife.59288.
 
(1) Nichols, R. J.; LaFrance, B.; Phillips, N. R.; Radford, D. R.; Oltrogge, L. M.; Valentin-Alvarado, L. E.; Bischoff, A. J.; Nogales, E.; Savage, D. F. Discovery and Characterization of a Novel Family of Prokaryotic Nanocompartments Involved in Sulfur Metabolism. eLife 2021, 10, e59288. https://doi.org/10.7554/eLife.59288.
  
−
(2) (2)Choi, H.; Eom, S.; Kim, H.; Bae, Y.; Jung, H. S.; Kang, S. Load and Display: Engineering Encapsulin as a Modular Nanoplatform for Protein-Cargo Encapsulation and Protein-Ligand Decoration Using Split Intein and SpyTag/SpyCatcher. Biomacromolecules 2021, 22 (7), 3028–3039. https://doi.org/10.1021/acs.biomac.1c00481.
+
(2) Choi, H.; Eom, S.; Kim, H.; Bae, Y.; Jung, H. S.; Kang, S. Load and Display: Engineering Encapsulin as a Modular Nanoplatform for Protein-Cargo Encapsulation and Protein-Ligand Decoration Using Split Intein and SpyTag/SpyCatcher. Biomacromolecules 2021, 22 (7), 3028–3039. https://doi.org/10.1021/acs.biomac.1c00481.

Latest revision as of 22:10, 1 October 2024

SmBiT-Encapsulin2A

This part along with BBa_K5330021 are the two components of a test for Mycobacterium avium subspecies paratuberculosis (MAP.) This part is composed of a type 2A encapsulin (from MAP) with a linker to a SmBiT with a total molecular weight of 37kDa. The SmBiT is half of a split luciferase. This acts as a reporter system for cage formation of Encapsulins linked to either LgBiT or SmBiT so when they come together in the presence of NanoGlo© reagents, they produce light. With both SmBiT-Encap2A and LgBiT-Encap2A present in the test, light output is detected (see Figure 1).

Figure 1: Negative Test Diagram (no presence of MAP Encapsulin monomers).

When a blood sample of a cow infected with Johnes diseases is introduced into this solution, there should be a detected loss of light. This is because Encapsulin monomers from MAP will rearrange to incorporate our engineered monomers (SmBiT-Encap2A and LgBiT-Encap2A) resulting in distance being introduced between halves of the split luciferase and either less or no light produced at all (see Figure 2). This occurs due to the lability in exchange of monomers in encapsulin cages allowing interconversion of MAP encapsulin and our engineered ones.

Figure 2: Positive Test Diagram (presence of MAP Encapsulin monomers eg. a MAP infected blood sample).

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 79
  • 1000
    COMPATIBLE WITH RFC[1000]

Design considerations

In the design of this fusion protein there were a few things we had to consider. Type 2A encapsulins are much less well characterised as Type 1 encapsulins. This meant differentiating between the two in terms of size of cages, overall charge and pore size and location.

Figure 2: Overlay of Type 1 and Type 2 Encapsulin monomers to show homology and heterology in structure(1).

Figure 3: Type 2 Encapsulins (left) and Type 1 Encapsulins (right) in their cage formations(1).

Then we decided how long we wanted our linker; did we want more flexibility, or did we want a bit more control over how far we can reach with the two split luciferase parts. We found a paper(2) where they attached NanoLuc to type 1 encapsulins to detect cage formation. From there, we copied their linker design (for which they did not describe the rational for) to attach our split luciferase parts and our type 2A encapsulin monomers.

Figure 4: Type 2 Encapsulins attached to SmBiT.

We have since encountered problems in our protein purification using His tag purification on immobilised metal affinity chromatography. We think our His tag should have been on the C terminus (rather that the N terminus it currently is on.) This has lead to a less efficient purification with a lot of protein lost in the follow-through. For information of experimental data collected from this part, see the design page.

This part is currently produced in a PC2 lab due to the production being from a GMO. This part was produced in SHuffle® T7 Competent E. coli due to their enhanced protein expression and folding ability. As of the registry freeze, we are yet to achieve proof of concept due to complications in LgBiT purification.

Sources

Encapsulin Type 2A = UniProt ID I3NID5 · ENCP2_MYCPA

Linker = (2)

SmBiT = IGEM Registry BBa_K1761006

(1) Nichols, R. J.; LaFrance, B.; Phillips, N. R.; Radford, D. R.; Oltrogge, L. M.; Valentin-Alvarado, L. E.; Bischoff, A. J.; Nogales, E.; Savage, D. F. Discovery and Characterization of a Novel Family of Prokaryotic Nanocompartments Involved in Sulfur Metabolism. eLife 2021, 10, e59288. https://doi.org/10.7554/eLife.59288.

(2) Choi, H.; Eom, S.; Kim, H.; Bae, Y.; Jung, H. S.; Kang, S. Load and Display: Engineering Encapsulin as a Modular Nanoplatform for Protein-Cargo Encapsulation and Protein-Ligand Decoration Using Split Intein and SpyTag/SpyCatcher. Biomacromolecules 2021, 22 (7), 3028–3039. https://doi.org/10.1021/acs.biomac.1c00481.